The Met66 allele of the functional Val66Met polymorphism in the brain-derived neurotrophic factor gene confers protection against neurocognitive dysfunction in systemic lupus erythematosus

Annals of the Rheumatic Diseases

Volumn 65, Issue 10, 2006, Pages 1330-1335

  Oroszi, G ^b   Lapteva, L ^c   Davis, E ^b   Yarboro, C H ^c   Weickert, T ^d   Roebuck Spencer, T ^e   Bleiberg, J ^e   Rosenstein, D ^d   Pao, M ^d   Lipsky, P E ^c   Goldman, D ^b   Lipsky, R H ^b   Illei, G G ^a,c  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^e NATIONAL REHABILITATION HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; METHIONINE; PREDNISONE; VALINE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; ATTENTION; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DEPTH PERCEPTION; DNA POLYMORPHISM; ETHNIC DIFFERENCE; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; MOTOR PERFORMANCE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; PSYCHOMOTOR ACTIVITY; SEX DIFFERENCE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ALLELES; ATTENTION; BRAIN-DERIVED NEUROTROPHIC FACTOR; COGNITION DISORDERS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MALE; MIDDLE AGED; MOTOR SKILLS; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, GENETIC; PSYCHOMOTOR PERFORMANCE;

EID: 33749995605     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.051623     Document Type: Article

References (42)

1. Kozora E, Thompson LL, West SG, Kotzin BL. Analysis of cognitive and psychological deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum 1996;39:2035-45.
2. Brey RL, Holliday SL, Saklad AR, Navarrete MG, Hermosillo-Romo D, Stallworth CL, et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002;58:1214-20.
3. Carbotte RM, Denburg SD, Denburg JA. Prevalence of cognitive impairment in systemic lupus erythematosus. J Nerv Ment Dis 1986;174:357-64.
4. Denburg SD, Carbotte RM, Ginsberg JS, Denburg JA. The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus. J Int Neuropsychol Soc 1997;3:377-86.
5. Menon S, Jameson-Shortall E, Newman SP, Hall-Craggs MR, Chinn R, Isenberg DA. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum 1999;42:735-41.
6. Carlomagno S, Migliaresi S, Ambrosone L, Sannino M, Sanges G, Di Iorio G. Cognitive impairment in systemic lupus erythematosus: a follow-up study. J Neurol 2000;247:273-9.
7. Ginsburg KS, Wright EA, Larson MG, Fossel AH, Albert M, Schur PH, et al. A controlled study of the prevalence of cognitive dysfunction in randomly selected patients with systemic lupus erythematosus. Arthritis Rheum 1992;35:776-82.
8. Denburg JA, Behmann SA. Lymphocyte and neuronal antigens in neuropsychiatric lupus: presence of an elutable, immunoprecipitable lymphocyte/neuronal 52 kd reactivity. Ann Rheum Dis 1994;53:304-8.
9. Denburg JA, Carbotte RM, Denburg SD. Neuronal antibodies and cognitive function in systemic lupus erythematosus. Neurology 1987;37:404-7.
10. Fisk JD, Eastwood B, Sherwood G, Hanly JG. Patterns of cognitive impairment in patients with systemic lupus erythematosus. Br J Rheumatol 1993;32:458-62.
11. Monastero R, Bettini P, Del Zotto E, Cottini E, Tincani A, Balestrieri G, et al. Prevalence and pattern of cognitive impairment in systemic lupus erythematosus patients with and without overt neuropsychiatric manifestations. J Neurol Sci 2001;184:33-9.
12. Lapteva L, Nowak M, Yarboro CH, Takada K, Roebuck T, Weickert T, et al. Anti-N-methyl-D Aspartate (NMDA) receptor antibodies, cognitive dysfuntion and depression in systemic lupus erythematosus. Arthritis Rheum 2006;54:2505-14.
13. Ernfors P, Ibanez CF, Ebendal T, Olson L, Persson H. Molecular cloning and neurotrophic activities of a protein with structural similarities to nerve growth factor: developmental and topographical expression in the brain. Proc Natl Acad Sci USA 1990;87:5454-8.
14. Murer MG, Yan Q, Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 2001;63:71-124.
15. Jones KR, Reichardt LF. Molecular cloning of a human gene that is a member of the nerve growth factor family. Proc Natl Acad Sci USA 1990;87:8060-4.
16. Leibrock J, Lottspeich F, Hohn A, Hofer M, Hengerer B, Masiakowski P, et al. Molecular cloning and expression of brain-derived neurotrophic factor. Nature 1989;341:149-52.
17. Ventimiglia R, Mather PE, Jones BE, Lindsay RM. The neurotrophins BDNF, NT-3 and NT-4/5 promote survival and morphological and biochemical differentiation of striatal neurons in vitro. Eur J Neurosci 1995;7:213-22.
18. Yamada K, Mizuno M, Nabeshima T. Role for brain-derived neurotrophic factor in learning and memory. Life Sci 2002;70:735-44.
19. Lu B, Gottschalk W. Modulation of hippocampal synaptic transmission and plasticity by neurotrophins. Prog Brain Res 2000;128:231-41.
20. Pang PT, Lu B. Regulation of late-phase LTP and long-term memory in normal and aging hippocampus: role of secreted proteins tPA and BDNF. Ageing Res Rev 2004;3:407-30.
21. Poo MM. Neurotrophins as synaptic modulators. Nat Rev Neurosci 2001;2:24-32.
22. Shimizu E, Hashimoto K, Iyo M. Ethnic difference of the BDNF 196G/A (val66met) polymorphism frequencies: the possibility to explain ethnic mental traits. Am J Med Genet 2004;126B:122-3.
23. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003;112:257-69.
24. Maier M, Ron MA, Barker GJ, Tofts PS. Proton magnetic resonance spectroscopy: an in vivo method of estimating hippocampal neuronal depletion in schizophrenia. Psychol Med 1995;25:1201-9.
25. Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, Egan MF, et al. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 2003;23:6090-4.
26. Pezawas L, Verchinski BA, Mattay VS, Callicott JH, Kolachana BS, Straub RE, et al. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci 2004;24:10099-102.
27. Szeszko PR, Lipsky R, Mentschel C, Robinson D, Gunduz-Bruce H, Sevy S, et al. Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formation. Mol Psychiatry 2005;10:631-0.
28. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
29. Shi MM, Myrand SP, Bleavins MR, de la Iglesia FA. High throughput genotyping for the detection of a single nucleotide polymorphism in NAD(P)H quinone oxidoreductase (DT diaphorase) using TaqMan probes. Mol Pathol 1999;52:295-9.
30. Chen ZY, Patel PD, Sant G, Meng CX, Teng KK, Hempstead BL, et al. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci 2004;24:4401-11.
31. Jiang X, Xu K, Hoberman J, Tian F, Marko AJ, Waheed JF, et al. BDNF variation and mood disorders: a novel functional promoter polymorphism and Val66Met are associated with anxiety but have opposing effects. Neuropsychopharmacology 2005;30:1353-61.
32. Hall D, Dhilla A, Charalambous A, Gogos JA, Karayiorgou M. Sequence variants of the brain-derived neurotrophic factor (BDNF) gene are strongly associated with obsessive-compulsive disorder. Am J Hum Genet 2003;73:370-6.
33. Sklar P, Gabriel SB, McInnis MG, Bennett P, Lim YM, Tsan G, et al. Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Brain-derived neutrophic factor. Mol Psychiatry 2002;7:579-93.
34. Neves-Pereira M, Mundo E, Muglia P, King N, Macciardi F, Kennedy JL. The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. Am J Hum Genet 2002;71:651-5.
35. Geller B, Badner JA, Tillman R, Christian SL, Bolhofner K, Cook EH Jr. Linkage disequilibrium of the brain-derived neurotrophic factor Val66Met polymorphism in children with a prepubertal and early adolescent bipolar disorder phenotype. Am J Psychiatry 2004;161:1698-700.
36. Sen S, Nesse RM, Stoltenberg SF, Li S, Gleiberman L, Chakravarti A, et al. A BDNF coding variant is associated with the NEO personality inventory domain neuroticism, a risk factor for depression. Neuropsychopharmacology 2003;28:397-401.
37. Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci 2003;4:299-309.
38. Friedman WJ, Greene LA. Neurotrophin signaling via Trks and p75. Exp Cell Res 1999;253:131-42.
39. Beattie MS, Harrington AW, Lee R, Kim JY, Boyce SL, Longo FM, et al. ProNGF induces p75-mediated death of oligodendrocytes following spinal cord injury. Neuron 2002;36:375-86.
40. Lee R, Kermani P, Teng KK, Hempstead BL. Regulation of cell survival by secreted proneurotrophins. Science 2001;294:1945-8.
41. Bui NT, Konig HG, Culmsee C, Bauerbach E, Poppe M, Krieglstein J, et al. p75 neurotrophin receptor is required for constitutive and NGF-induced survival signalling in PC12 cells and rat hippocampal neurones. J Neurochem 2002;81:594-605.
42. Lu B. Pro-region of neurotrophins: role in synaptic modulation. Neuron 2003;39:735-8.